• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Modeling and simulation at the interface of nonclinical and early clinical drug development.

作者信息

Visser S A G, Manolis E, Danhof M, Kerbusch T

机构信息

1] Global DMPK, Innovative Medicines, AstraZeneca R&D, Södertälje, Sweden [2] Current affiliation: Merck Research Laboratories, Merck & Co., Inc., Upper Gwynedd, PA, USA.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2(2):e30. doi: 10.1038/psp.2013.3.

DOI:10.1038/psp.2013.3
PMID:23835941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3600756/
Abstract
摘要

相似文献

1
Modeling and simulation at the interface of nonclinical and early clinical drug development.非临床与早期临床药物开发界面的建模与模拟
CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2(2):e30. doi: 10.1038/psp.2013.3.
2
An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates.抗体药物偶联物非临床开发的法规及非临床方面介绍
Pharm Res. 2015 Nov;32(11):3584-92. doi: 10.1007/s11095-015-1742-y. Epub 2015 Jun 25.
3
Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.从临床前到临床开发的转化药代动力学-药效学建模：以抗癌药物克唑替尼为例。
AAPS J. 2013 Apr;15(2):354-66. doi: 10.1208/s12248-012-9436-4. Epub 2012 Dec 19.
4
Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.从实验室到临床的分子靶向小分子抗癌药物的转化建模与模拟方法
Expert Opin Drug Metab Toxicol. 2016;12(3):253-65. doi: 10.1517/17425255.2016.1141895.
5
Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration into Clinical Dose Optimization and Toxicity Management.小分子肿瘤药物的非临床评价：整合到临床剂量优化和毒性管理中。
Clin Cancer Res. 2016 Jun 1;22(11):2618-22. doi: 10.1158/1078-0432.CCR-15-2645.
6
Antibody-drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays.抗体药物偶联物的非临床支持：从早期到晚期非临床生物分析的配体结合测定法
Bioanalysis. 2015;7(13):1605-17. doi: 10.4155/bio.15.107.
7
Considerations on nonclinical approaches to modeling risk factors of suicidal ideation and behavior.关于自杀意念和行为风险因素建模的非临床方法的思考
Regul Toxicol Pharmacol. 2017 Oct;89:288-301. doi: 10.1016/j.yrtph.2017.07.030. Epub 2017 Jul 27.
8
Prediction of clinical risks by analysis of preclinical and clinical adverse events.通过分析临床前和临床不良事件预测临床风险。
J Biomed Inform. 2015 Apr;54:167-73. doi: 10.1016/j.jbi.2015.02.008. Epub 2015 Mar 5.
9
Nonclinical & clinical interface - extrapolation of nonclinical data to support Phase I clinical studies.非临床与临床的衔接——从非临床数据外推以支持 I 期临床研究。
Regul Toxicol Pharmacol. 2021 Apr;121:104869. doi: 10.1016/j.yrtph.2021.104869. Epub 2021 Jan 20.
10
Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.从制药行业角度看，全面整合非临床-临床风险评估以简化 QT 延长相关责任判定的时机已到。
Clin Pharmacol Ther. 2021 Feb;109(2):310-318. doi: 10.1002/cpt.2029. Epub 2020 Sep 24.

引用本文的文献

1
The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia.在肺炎背景下，利用转化建模与模拟来开发免疫调节疗法作为抗生素治疗的辅助手段。
Pharmaceutics. 2021 Apr 22;13(5):601. doi: 10.3390/pharmaceutics13050601.
2
Clinical pharmacology applications in clinical drug development and clinical care: A focus on Saudi Arabia.临床药理学在临床药物研发与临床护理中的应用：以沙特阿拉伯为重点
Saudi Pharm J. 2020 Oct;28(10):1217-1227. doi: 10.1016/j.jsps.2020.08.012. Epub 2020 Aug 21.
3
The promises of quantitative systems pharmacology modelling for drug development.定量系统药理学建模在药物研发中的前景。
Comput Struct Biotechnol J. 2016 Sep 23;14:363-370. doi: 10.1016/j.csbj.2016.09.002. eCollection 2016.
4
In Silico Pharmacology.计算机药理学
Am Health Drug Benefits. 2016 May;9(3):126-7.
5
Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation.模型引导的药物发现与开发中的良好实践：实践、应用与文档记录
CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):93-122. doi: 10.1002/psp4.12049. Epub 2016 Mar 14.
6
Agent-Based Modeling in Systems Pharmacology.系统药理学中的基于主体的建模
CPT Pharmacometrics Syst Pharmacol. 2015 Nov;4(11):615-29. doi: 10.1002/psp4.12018. Epub 2015 Nov 13.
7
Implementation of quantitative and systems pharmacology in large pharma.大型制药公司中定量与系统药理学的实施。
CPT Pharmacometrics Syst Pharmacol. 2014 Oct 22;3(10):e142. doi: 10.1038/psp.2014.40.
8
Regulatory modeling and simulation moves into the next gear in europe.监管建模与模拟在欧洲进入下一个阶段。
CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2(2):e32. doi: 10.1038/psp.2013.8.
9
Modeling and simulation in clinical pharmacology and dose finding.临床药理学和剂量发现中的建模与仿真。
CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2(2):e29. doi: 10.1038/psp.2013.5.
10
Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims.建模与模拟，用于优化确证性试验的设计与分析、表征风险效益并支持标签声明。
CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2(2):e27. doi: 10.1038/psp.2013.4.

本文引用的文献

1
The Role of Modeling and Simulation in Development and Registration of Medicinal Products: Output From the EFPIA/EMA Modeling and Simulation Workshop.模型和模拟在药品开发和注册中的作用：来自 EFPIA/EMA 模型和模拟研讨会的结果。
CPT Pharmacometrics Syst Pharmacol. 2013 Feb 27;2(2):e31. doi: 10.1038/psp.2013.7.
2
CPT: Pharmacometrics and Systems Pharmacology.CPT：药物代谢动力学与系统药理学。
CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1(9):e8. doi: 10.1038/psp.2012.8.
3
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival.药物的传递能否得到改善？提高 II 期生存率的基础药代动力学和药理学原则。
Drug Discov Today. 2012 May;17(9-10):419-24. doi: 10.1016/j.drudis.2011.12.020. Epub 2011 Dec 29.
4
New pathway for qualification of novel methodologies in the European Medicines Agency.新的途径来确定欧洲药品管理局的新方法的资格。
Proteomics Clin Appl. 2011 Jun;5(5-6):248-55. doi: 10.1002/prca.201000130. Epub 2011 Apr 28.
5
Systems biology and pharmacology.系统生物学与药理学。
Clin Pharmacol Ther. 2010 Jul;88(1):17-9. doi: 10.1038/clpt.2010.69.
6
Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations.药代动力学和动态推理的早期整合对于先导化合物的优化开发至关重要：战略考量。
Drug Discov Today. 2009 Apr;14(7-8):358-72. doi: 10.1016/j.drudis.2008.12.011. Epub 2009 Jan 20.
7
Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies.从早期药物开发中获取药代动力学和药效学数据：设计信息丰富的人体药理学研究。
Clin Pharmacokinet. 2008;47(6):373-81. doi: 10.2165/00003088-200847060-00002.
8
On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development.根据临床前及早期药物开发中先前临床信息预测首次人体试验中的人体剂量。
Xenobiotica. 2007 Oct-Nov;37(10-11):1331-54. doi: 10.1080/00498250701648008.
9
Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.基于机制的药代动力学-药效学建模：生物相分布、受体理论和动力学系统分析。
Annu Rev Pharmacol Toxicol. 2007;47:357-400. doi: 10.1146/annurev.pharmtox.47.120505.105154.